Mitchell Hickman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitchell Hickman has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Agostino Cristaudo
Department of Radiation Oncology, University of Pisa, 56100 Pisa PI, Italy
1 shared publication - Andrew Hartley
Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, UK
1 shared publication - Charles Fong
Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham B15 2TH, UK
1 shared publication - Paul Sanghera
Hall-Edwards Radiotherapy Research Group, Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK
1 shared publication
Latest Publications
- Open Access
Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer
Integrating immunotherapy, proton therapy and biological dose escalation into the definitive chemoradiation of oropharyngeal cancer poses several challenges. Reliable and reproducible data must be obtained in a timely fashion. However, despite recent international radiotherapy contouring guidelines, controversy persists as to the applicability of such guidelines to all cases. Similarly, a lack of consensus exists concerning both the definition of the organ at risk for oral mucositis and the most appropriate endpoint to measure for this critical toxicity. Finally, the correlation between early markers of efficacy such as complete response on PET CT following treatment and subsequent survival needs elucidation for biological subsets of oropharyngeal cancer.
Open AccessAssessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer
Integrating immunotherapy, proton therapy and biological dose escalation into the definitive chemoradiation of oropharyngeal cancer poses several challenges. Reliable and reproducible data must be obtained in a timely fashion. However, despite recent international radiotherapy contouring guidelines, controversy persists as to the applicability of such guidelines to all cases. Similarly, a lack of consensus exists concerning both the definition of the organ at risk for oral mucositis and the most appropriate endpoint to measure for this critical toxicity. Finally, the correlation between early markers of efficacy such as complete response on PET CT following treatment and subsequent survival needs elucidation for biological subsets of oropharyngeal cancer.